Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Corcoy, R; Mendoza, LC; Simmons, D; Desoye, G; Adelantado, JM; Chico, A; Devlieger, R; van Assche, A; Galjaard, S; Timmerman, D; Lapolla, A; Dalfra, MG; Bertolotto, A; Harreiter, J; Wender-Ozegowska, E; Zawiejska, A; Kautzky-Willer, A; Dunne, FP; Damm, P; Mathiesen, ER; Jensen, DM; Andersen, LLT; Tanvig, M; Hill, DJ; Jelsma, JG; Snoek, FJ; Köfeler, H; Trötzmüller, M; Lips, P; van Poppel, MNM.
The DALI vitamin D randomized controlled trial for gestational diabetes mellitus prevention: No major benefit shown besides vitamin D sufficiency.
CLIN NUTR. 2020; 39(3): 976-984. Doi: 10.1016/j.clnu.2019.04.006
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Desoye Gernot; Köfeler Harald; Trötzmüller Martin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: As vitamin D deficiency is associated with an increased risk of gestational diabetes mellitus (GDM), we aimed to test vitamin D supplementation as a strategy to reduce GDM risk (evaluated after fasting plasma glucose (FPG), insulin resistance and weight gain) in pregnant overweight/obese women. The DALI vitamin D multicenter study enrolled women with prepregnancy body mass index (BMI) ≥ 29 kg/m², ≤19 + 6 weeks of gestation and without GDM. Participants were randomized to receive 1600 IU/day vitamin D3 or placebo (each with or without lifestyle intervention) on top of (multi)vitamins supplements. Women were assessed for vitamin D status (sufficiency defined as serum 25-hydroxyvitamin D (25(OH)D) ≥ 50 nmol/l), FPG, insulin resistance and weight at baseline, 24-28 and 35-37 weeks. Linear or logistic regression analyses were performed to assess intervention effects. Average baseline serum 25(OH)D was ≥50 nmol/l across all study sites. In the vitamin D intervention arm (n = 79), 97% of participants achieved target serum vitamin 25(OH)D (≥50 nmol/l) at 24-28 weeks and 98% at 35-37 weeks vs 74% and 78% respectively in the placebo arm (n = 75, p < 0.001). A small but significantly lower FPG (-0.14 mmol/l; CI95 -0.28, -0.00) was observed at 35-37 weeks with the vitamin D intervention without any additional difference in metabolic status, perinatal outcomes or adverse event rates. In the DALI vitamin D trial, supplementation with 1600 IU vitamin D3/day achieved vitamin D sufficiency in virtually all pregnant women and a small effect in FPG at 35-37 weeks. The potential of vitamin D supplementation for GDM prevention in vitamin D sufficient populations appears to be limited. ISRCTN70595832. Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Find related publications in this database (Keywords): Vitamin D supplementation; Vitamin D sufficiency; Pregnancy; Fasting plasma glucose; Fasting plasma insulin; Gestational diabetes mellitus